WO1999001423A1 - Antagonistes/agonistes inverses du glucagon - Google Patents

Antagonistes/agonistes inverses du glucagon Download PDF

Info

Publication number
WO1999001423A1
WO1999001423A1 PCT/DK1998/000287 DK9800287W WO9901423A1 WO 1999001423 A1 WO1999001423 A1 WO 1999001423A1 DK 9800287 W DK9800287 W DK 9800287W WO 9901423 A1 WO9901423 A1 WO 9901423A1
Authority
WO
WIPO (PCT)
Prior art keywords
lower alkyl
γçö
aryl
hydrogen
compound according
Prior art date
Application number
PCT/DK1998/000287
Other languages
English (en)
Other versions
WO1999001423A8 (fr
Inventor
Anthony Ling
Vlad Gregor
Javier Gonzales
Yufeng Hong
Dan Kiel
Atsuo Kuki
Shenghua Shi
Lars Naerum
Peter Madsen
Christian Sams
Jesper Lau
Michael Bruno Plewe
Jun Feng
Min Teng
Michael David Johnson
Kimberly Ann Teston
Ulla Grove Sidelmann
Lotte Bjerre Knudsen
Original Assignee
Novo Nordisk A/S
Agouron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S, Agouron Pharmaceuticals, Inc. filed Critical Novo Nordisk A/S
Priority to BR9810378-4A priority Critical patent/BR9810378A/pt
Priority to JP50616099A priority patent/JP2003514508A/ja
Priority to CA002294046A priority patent/CA2294046A1/fr
Priority to AU79083/98A priority patent/AU749271B2/en
Priority to HU0002373A priority patent/HUP0002373A3/hu
Priority to EP98929244A priority patent/EP0994848A1/fr
Priority to IL13337798A priority patent/IL133377A0/xx
Publication of WO1999001423A1 publication Critical patent/WO1999001423A1/fr
Publication of WO1999001423A8 publication Critical patent/WO1999001423A8/fr
Priority to NO996550A priority patent/NO996550L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/45—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms doubly-bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to agents that act to antagonize the action of the giucagon peptide hormone. It relates particularly to non-peptide giucagon antagonists or inverse agonists.
  • Giucagon is a key hormonal agent that, in cooperation with insulin, mediates homeostatic regulation of the amount of glucose in the blood. Giucagon primarily acts by stimulating certain cells (mostly liver cells) to release glucose when blood glucose levels fall. The action of giucagon is opposed by insulin which stimulates cells to take up and store glucose whenever blood glucose levels rise. Both giucagon and insulin are peptide hormones.
  • Giucagon is produced in the alpha islet cells and insulin in the beta islet cells of the pancreas.
  • Diabetes mellitus the common disorder of glucose metabolism, is characterized by hypergly- cemia, and can present as type I, insulin-dependent, or type II, a form that is non-insulin- dependent in character.
  • Subjects with type I diabetes are hyperglycemic and hypoinsulinemic, and the conventional treatment for this form of the disease is to provide insulin.
  • absolute or relative elevated giucagon levels have been shown to contribute to the hyperglycemic state.
  • giucagon can be suppressed by providing an antagonist or an inverse agonist, substances that inhibit or prevent giucagon induced response.
  • the antagonist can be peptide or non-peptide in nature.
  • Native giucagon is a 29 amino acid- containing peptide having the sequence: His-Ser-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp- Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-NH 2 .
  • Giucagon exerts its action by binding to and activating its receptor, which is part of the Glu- cagon-Secretin branch of the 7-transmembrane G-protein coupled receptor family (Jelinek et al. Science 259, 1614, (1993)).
  • the receptor functions by activation of the adenylyl cyclase second messenger system and the result is an increase in cA P levels.
  • Peptide antagonists of peptide hormones are often quite potent; however, they are defective as drugs because of degradation by physiological enzymes, and poor biodistribution. Therefore, non-peptide antagonists of the peptide hormones are preferred.
  • non-peptide glu- cagon antagonists a quinoxaline derivative, (2-styryl-3-[3-(dimethylamino)propylmethyl- amino]-6,7-dichloroquinoxaline was found to displace giucagon from the rat liver receptor (Collins, J.L. et al. (1992) Bioorganic and Medicinal Chemistry Letters 2(9):915-918). West, R.R.- et al.
  • WO 94/14426 discloses use of skyrin, a natural product comprising a pair of linked 9,10-anthracenedione groups, and its synthetic analogues, as giucagon antagonists.
  • Anderson, P.L., U.S. Patent No. 4,359,474 discloses the giucagon antagonistic properties of 1- phenyl pyrazole derivatives.
  • Barcza, S., U.S. Patent No. 4,374,130 discloses substituted disi- lacyclohexanes as giucagon antagonists.
  • WO 98/04528 (Bayer Corporation) discloses substituted pyridines and biphenyls as giucagon antagonists.
  • WO 97/16442 discloses substituted pyridyl pyrroles as giucagon antagonists
  • WO 98/21957 discloses 2,4-diaryl-5-pyridylimidazoles as giucagon antagonists. These giucagon antagonists differ structurally from the present compounds. Description of the invention
  • Halogen designates an atom selected from the group consisting of F, Cl, Br or I.
  • alkyl in the present context designates a hydrocarbon chain or a ring that is either saturated or unsaturated (containing one or more double or triple bonds where feasible) of from 1 to 10 carbon atoms in either a linear or branched or cyclic configuration.
  • alkyl includes for example n-octyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, allyl, propargyl, 2- hexynyl, cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclohexyl, cyclooctyl, 4-cyclohexylbutyl, and the like.
  • non-limiting examples are sec-butyl, n-pentyl, isopentyl, neopentyl, te/ ⁇ -pentyl, n- hexyl, isohexyl, n-heptyl, n-nonyl, n-decyl, vinyl, 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-met.hyl-2-but.enyl, 1- hexenyl, 3-hexenyl, 2,4-hexadienyl, 5-hexenyl, 1-heptenyl, 2,4-heptadienyl, 1-octenyl, 2,4- octadienyi, ethynyl, 1-propynyl, 1-butynyl, 2-butyn
  • lower alkyl designates a hydrocarbon moiety specified above, of from 1 to 6 carbon atoms.
  • Aryl means an aromatic ring moiety, for example: phenyl, naphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazolyl, imidazolyl, pyrazinyl, pyridazinyl, 1 ,2,3-triazinyl, 1 ,2,4-triazinyl, oxazolyl, isoxazolyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,3,4-oxadiazolyl, 1 ,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl, 1 ,3,4-thiadiazolyl, thiazolyl, isothiazolyl, tetrazolyl, 1-H-tetrazol-5-yl, indolyl, quinolyl, quinazolinyl, benzofuryl, be
  • Non-limiting examples are biphenyl, anthracenyl, phenanthrenyl, fluorenyl, indenyl, 1 ,2,3,4-tetrahydronaphthyl, 2,3-dihydrobenzofuryl, triazolyl, pyranyl, thiadiazinyl, isoindolyl, in- dazolyl, 1 ,2,5-oxadiazolyl, 1 ,2,5-thiadiazolyl, benzothienyl, benzimidazolyl, benzthiazolyl, ben- maiothiazolyl, benzoxazolyl, benzisoxazolyl, purinyl, quinolizinyl, isoquinolyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, pyrrolinyl, pyrazolinyl, indolinyl, pyrrolidinyl
  • the aryl moieties are optionally substituted by one or more substituents, for example selected from the group consisting of F, Cl, I, and Br; lower alkyl; lower alkanoyl such as formyl, acetyl, propionyl, butyryl, valeryl, hexanoyl and the like; -OH; -NO 2 ; -CN; -CO 2 H; -O-lower alkyl; aryl; aryl-lower alkyl; -CO 2 CH 3 ; -CONH 2 ; -OCH 2 CONH 2 ; -NH 2 ; -N(CH 3 ) 2 ; -SO 2 NH 2 ; -OCHF 2 ; -CF 3 ; -OCF 3 and the like.
  • Such aryl moieties may also be substituted by two substituents forming a bridge, for example -OCH 2 O-.
  • Aryl-lower alkyl means a lower alkyl as defined above, substituted by an aryl, for example:
  • the aryl group is optionally substituted as described above.
  • the present invention is based on the unexpected observation that compounds having a selected nitrogen-bearing central motif and the general structural features disclosed below antagonize the action of giucagon. Accordingly, the invention is concerned with compounds of the general formula
  • R 1 and R 2 independently are hydrogen or lower alkyl or together form a valence bond
  • R 3 and R 4 independently are hydrogen or lower alkyl
  • n 0, 1, 2 or 3;
  • n 0 or 1 ;
  • R 5 is hydrogen, lower alkyl, aryl-lower alkyl or -OR 6 ;
  • R 6 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 7 is hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 11 , -NR 11 R 12 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SO 2 NR 11 R 12 , -SR 11 , -CHF 2 , -OCHF 2 , -OSO 2 R 11 , -CONR 11 R 12 , -OCH 2 CONR 11 R 12 , -CH 2 OR 11 , -CH 2 NR 11 R 12 , -OCOR 11 , -CO 2 R 13 or -OSO 2 CF 3 ;
  • R 8 and R 9 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 11 , -NR 11 R 12 , lower alkyl, aryl, -SCF 3 , -SR 11 , -CHF 2 , -OCHF 2 , -OSO 2 R 11 , -CONR 11 R 12 , -CH 2 OR 11 , -CH 2 NR 11 R 12 , -OCOR 11 , -CO 2 R 13 or -OSO 2 CF 3 , or R 8 and R 9 together form a bridge -OCH 2 O- or -OCH 2 CH 2 O-;
  • R 11 and R 12 independently are hydrogen, -COR 13 , -SO 2 R 13 , lower alkyl or aryl;
  • R 13 is hydrogen, lower alkyl, aryl-lower alkyl or aryl
  • R 10 is hydrogen, lower alkyl, aryl-lower alkyl or aryl;
  • R 14 and R 15 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3> -O(CH 2 ) ! CF 3 , -NO 2 , -OR 16 , -NR 16 R 17 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 16 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -OSO 2 CF 3 , -CONR 16 R 17 , -(CH 2 ),CONR 16 R 17 , -O(CH 2 ),CONR 16 R 17 , -(CH 2 ),COR 16 , -(CH 2 ),COR 16 , -(CH 2 ),COR 16 , -(CH 2 ),OR 16 , -O(CH 2 ),OR 16 , -(CH 2 ),NR 16 R 17 , -O(CH 2 ),NR 16 R 17 ,
  • I is 1 , 2, 3 or 4;
  • R 16 and R 17 independently are hydrogen, -COR 18 , -SO 2 R 18 , lower alkyl, aryl, or R 16 and R 17 together form a cyclic alkyl bridge containing from 2 to 7 carbon atoms;
  • R 18 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • Q is -NR 23 -, -O- or -S-;
  • R 19 , R 20 , R 21 and R 22 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 24 , -NR 24 R 25 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 24 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -OSO 2 CF 3 , -CONR 24 R 25 , -CH 2 CONR 24 R 25 , -OCH 2 CONR 24 R 25 , -CH 2 OR 24 , -CH 2 NR 4 R 25 , -OCOR 24 or -CO 2 R 24 , or R 19 and R 20 , R 20 and R 21 , or R 21 and R 22 together form a bridge -OCH 2 O-; wherein R 24 and R 25 independently are hydrogen, -COR 26 , -SO
  • R 26 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 23 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 3a , R 3b , R 4a and R 4b independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 24a , -NR 24a R 25a , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 24a , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2, -OSO 2 CF 3 , -CONR 24a R 25a , -CH 2 CONR 24a R 25a , -OCH 2 CONR 24a R 5a , -CH 2 OR 24a , -CH 2 NR 24a R 25a , -OCOR 24a or -CO 2 R 24a ;
  • R 24a and R 25a independently are hydrogen, -COR 26a , -SO 2 R 26a , lower alkyl, aryl or aryl-lower alkyl;
  • R 26a is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 3a and R 3b , R 4a and R 4b , or R 3a and R 4b together form a bridge -(CH 2 ) r ;
  • i is 1 , 2, 3 or 4;
  • a, b, c and d independently are 0, 1 , 2, 3 or 4; e, f and p independently are 0 or 1 ;
  • q 0, 1 or 2;
  • R 5a and R 5b independently are hydrogen, lower alkyl, -OH, -(CH 2 ) k -OR 6a , -COR 6a , -(CH 2 ) k -CH(OR 6a ) 2 , -(CH 2 ) k -CN, -(CH 2 ) k -NR 6a R 6b , aryl, aryl-lower alkyl, -(CH 2 ) g -COOR 43 or (CH 2 ) g -CF 3 ;
  • k is 1 , 2, 3 or 4;
  • R 6a and R 6b independently are hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • g 0, 1 , 2, 3 or 4;
  • R 43 is hydrogen or lower alkyl
  • G" is -OCH 2 CO-, -CH 2 CO-, -CO- or a valence bond
  • F' is >CR 38 - or >N-;
  • Q' is -NR 36 -, -O- or -S-;
  • R 27 , R 28 , R 32 , R 33 , R ⁇ and R 35 independently are hydrogen, halogen, -CN, -CF 3 , -O(CH 2 ) y CF 3 , -(CH 2 ) y NHCOCF 3 , -NO 2 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 29 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -OSO 2 R 29 , -OSO 2 CF 3 , -(CH 2 ) y CONR 29 R 30 , -O(CH 2 ) y CONR 29 R 30 , -(CH 2 ) y OR 29 , -(CH 2 ) y NR 29 R 30 , -OCOR 29 , -COR 29 or -CO 2 R 29 ;
  • R 27 and R 28 , R 32 and R 33 , R 33 and R 34 , or R 34 and R 35 together form a bridge -O(CH 2 ) y O-;
  • y is 0, 1 , 2, 3 or 4;
  • R 29 and R 30 independently are hydrogen, -COR 31 , -CO 2 R 31 , -SO 2 R 31 , lower alkyl, aryl or aryl-lower alkyl; wherein R 31 is hydrogen, lower alkyl, aryl or aryl-lower alkyl;
  • R 36 and R 39 independently are hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 38 is hydrogen, -OR 40 , -NR 40 R 41 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 40 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -CONR 40 R 41 , -(CH 2 ) X CONR 40 R 41 , -O(CH 2 ) X CONR 40 R 41 , -(CH 2 ) x OR 40 , -(CH 2 ) X NR 40 R 41 , -OCOR 40 or -C0 2 R 40 ;
  • x is 1 , 2, 3 or 4;
  • R 40 and R 41 independently are hydrogen, -COR 42 , -SO 2 R 42 , lower alkyl, aryl or aryl-lower alkyl;
  • R 42 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 19 , R 20 , R 21 , R 22 and R 23 may alternatively be re- placed by R 14 or R 1S , respectively.
  • R 32 , R 33 , R 34 , R 35 , R 36 , R 38 and R 39 may alternatively be replaced by R 27 or R 28 , respectively.
  • R 3 is preferably hydrogen.
  • R 4 is preferably hydrogen.
  • A is preferably selected from the group consisting of:
  • R 7 , R 8 , R 9 and R 10 are as defined for formula I.
  • A is more preferably
  • R 7 , R 8 and R are as defined for formula I.
  • R 7 is preferably halogen, lower alkyl, -OH, -NO 2 , -CN, -CO 2 H, -O-lower alkyl, aryl, aryl-lower alkyl, -CO 2 CH 3 , -CONH 2 , -OCH 2 CONH 2 , -NH 2 , -N(CH 3 ) 2 , -SO 2 NH 2 , -OCHF 2 , -CF 3 or -OCF 3 .
  • R 8 and R 9 are independently hydrogen, halogen, -OH, -NO 2 , -NH 2 , -CN, -OCF 3 , -SCF 3 , -CF 3 , -OCH 2 CF 3 , -O-lower alkyl such as methoxy and ethoxy, lower alkyl such as methyl and ethyl, or phenyl, and R 10 is hydrogen, lower alkyl or phenyl.
  • R 8 and R 9 are independently selected from hydrogen, halogen such as -F and -Cl, -O-lower alkyl such as methoxy and ethoxy, -NH 2 , -CNor -NO 2 , and R 10 is hydrogen.
  • R 8 and R 9 independently are hydrogen, halogen, -OH, -NO 2 , -NH 2 , -CN, -OCF 3 , -SCF 3 , -CF 3 , -OCH 2 CF 3 , -O-lower alkyl such as methoxy and ethoxy, lower alkyl such as methyl and ethyl, or phenyl, preferably hydrogen, halogen such as -F and -Cl, -O-lower alkyl such as methoxy and ethoxy, -NH 2 , -CNor -NO 2 .
  • R 8 is hydrogen, halogen such as -F or -Cl, -O-lower alkyl such as -OCH 3 or -OC 2 H 5 , -NH 2 , -CN or -NO 2 ; and R 9 is hydrogen or halogen such as -F or -Cl.
  • R 8 is halogen and R 9 is hydrogen.
  • R 4 , B, K, D and m are as defined for formula I and R 8 and R 9 are as defined for formula I and preferably as defined for the preferred embodiments of A above.
  • B is preferably:
  • V, W, Z, Y and Q are as defined for formula I;
  • R 14 and R 15 independently are hydrogen, halogen, -CF 3 ⁇ -OCF 3 , -OR 16 , -NR 16 R 17 , lower alkyl, aryl, aryl-lower alkyl, -OSO 2 CF 3 , -CONR 16 R 17 , -CH 2 OR 16 , -CH 2 NR 6 R 17 , -OCOR 16 or -CO 2 R 18 ; or R 14 and R 15 together form a bridge -OCH 2 O- or -(CH 2 ) r ;
  • Q is preferably -O- or -NH-.
  • V, W, Z, Y and Q are as defined for formula I;
  • R 14 and R 15 independently are hydrogen, halogen, -CF 3, -OCF 3 , -OR 16 , -NR 16 R 17 , lower alkyl, aryl, aryl-lower alkyl, -OS0 2 CF 3 , -CONR 16 R 17 , -CH 2 OR 16 , -CH 2 NR 6 R 17 , -OCOR 16 or -CO 2 R 18 ; or R 14 and R 15 together form a bridge -OCH 2 O- or -(CH 2 ) r ;
  • R 14 and R 15 independently are hydrogen, halogen, -CF 3, -OCF 3 , -OR 16 , -NR 16 R 17 , lower alkyl, aryl, aryl-lower alkyl, -OSO 2 CF 3 , -CONR 16 R 17 , -CH 2 OR 16 , -CH 2 NR 16 R 17 , -OCOR 16 or -CO 2 R 18 ; or R 14 and R 15 together form a bridge -OCH 2 O- or -(CH 2 ) r ;
  • I, R 6 , R 17 and R 18 are as defined for formula I; K, D and m are as defined for formula I; and
  • R 8 and R 9 are as defined for formula I and preferably as defined for the preferred embodiments of A above.
  • R 14 and R 15 are preferably independently hydrogen, halogen, lower alkyl, aryl such as phenyl, or -O-lower alkyl such as methoxy.
  • K is preferably bound in para-position and in the above formulae Villa and Vlllb, K is preferably bound at the nitrogen atom of the indole group.
  • K is preferably selected from the group consisting of:
  • R 3a , R 3 , R 4a , R 4b , R 5a , R 5b , a, b, c, d, p and q are as defined for formula I.
  • K is selected from the group consisting of:
  • R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , a, b, c, d, p and q are as defined for formula I.
  • R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , b, c, d, p and q are as defined for formula I.
  • R 5a and R 5 are preferably independently hydrogen, lower alkyl, -OH, -(CH 2 ) k OR 6a , aryl, aryl-lower alkyl, -CH 2 CF 3> -(CH 2 ) g -COOR 43 , -COOR 43 , -(CH 2 ) k - CN or -(CH 2 ) k -NR 6a R 6b wherein g, k, R 43 , R 6a and R 6 are as defined for formula I.
  • g and k are independently 1 , 2 or 3
  • R 6a and R 6b are independently hydrogen, lower alkyl such as methyl or ethyl, or aryl such as phenyl,
  • R 3a and R 3b are preferably independently hydrogen, halogen, -OH, -O-iower alkyl, -COO-lower alkyl, lower alkyl or aryl-lower alkyl.
  • R a and R b are preferably independently hydrogen, -CN, -CONH 2 , -(CH 2 )-N(CH 3 ) 2 , -O-lower alkyl, -CH 2 OH, -CH 2 O-aryl, -N(CH 3 ) 2 , -OH, -CO 2 -lower alkyl or lower alkyl.
  • D is preferably hydrogen
  • D is hydrogen
  • D is more preferably hydrogen
  • E and E' independently are >CHR 38 , >NR 39 or -O-;
  • F' is >CR 38 - or >N-; and
  • s, r, R 27 , R 28 , R 38 , R 39 , V, Y', Z', Q' and W * are as defined for formula I.
  • R 27 and R 28 are preferably independently hydrogen; halogen such as -Cl, -Br or -F; -CF 3 ; -OCF 3; -OCHF 2 ; -OCH 2 CF 3 ; -(CH 2 ) y NHCOCF 3 ; -NHCOCF 3 ; -CN; -NO 2 ; -COR 29 , -COOR 29 , -(CH 2 ) y OR 29 or -OR 29 wherein R 29 is hydrogen, aryl or lower alkyl and y is 1 , 2, 3 or 4; lower alkyl such as methyl, ethyl, 2-propenyl, isopropyl, tert-butyl or cyclohexyl; lower alkylthio; -SCF 3 ; aryl such as phenyl; -(CH 2 ) y NR 29 R 30 or -NR 29 R 30 wherein R 29 and R 30 independently are hydrogen, -COO-
  • R 1 and R 2 independently are hydrogen or lower alkyl or together form a valence bond
  • R 3 and R 4 independently are hydrogen or lower alkyl
  • n 0, 1 , 2 or 3;
  • n 0 or 1 ;
  • R 5 is hydrogen, lower alkyl, aryl-lower alkyl, or -OR 6 ;
  • R 6 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 7 is hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 11 , -NR 11 R 12 , lower alkyl, aryl, -SCF 3 , -SR 11 , -CHF 2 , -OCHF 2 , -OSO 2 R 11 , -CONR 11 R 12 , -CH 2 OR 11 , -CH 2 NR 1 R 12 , -OCOR 11 , -CO 2 R 13 , -OSO 2 CF 3 .
  • R 8 and R 9 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 11 , -NR 11 R 12 , lower alkyl, aryl, -SCF 3 , -SR 11 , -CHF 2 , -OCHF 2 , -OSO 2 R 11 , -CONR 11 R 12 , -CH 2 OR 11 , -CH 2 NR 1 R 12 , -OCOR 11 , -CO 2 R 13 , -OSO 2 CF 3 , or R 8 and R 9 together form a bridge -OCH 2 O-;
  • R 1 and R 12 independently are hydrogen, -COR 13 , -SO 2 R 13 , lower alkyl or aryl;
  • R 13 is hydrogen, lower alkyl, aryl-lower alkyl or aryl;
  • R 10 is hydrogen, lower alkyl, aryl-lower alkyl or aryl;
  • R 14 and R 15 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -O(CH 2 )
  • R 14 and R 5 preferably independently representing hydrogen, halogen, -CF 3, -OCF 3 , -OR 16 , -NR 16 R 17 , lower alkyl, aryl, aryl-lower alkyl, -OSO 2 CF 3 , -CONR 16 R 17 , -CH 2 OR 16 , -CH 2 NR 16 R 17 , -OCOR 16 or -CO 2 R 18 ; or together forming a bridge -OCH 2 O-;
  • I is 1 , 2, 3 or 4;
  • R 16 and R 17 independently are hydrogen, -COR 18 , -SO 2 R 18 , lower alkyl, aryl, or R 16 and R 17 together form a cyclic alkyl bridge containing from 2 to 7 carbon atoms;
  • R 18 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • Q is -NR 23 -, -O- or -S-;
  • R 19 , R 20 , R 2 and R 22 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 24 , -NR 24 R 25 , lower alkyl, aryl, aryl-lower alkyl, SCF 3 , -SR 24 , -CHF 2 , -OCHF 2 , OCF 2 CHF 2 , -OSO 2 CF 3 , -CONR 24 R 25 , -CH 2 CONR 24 R 25 , -OCH 2 CONR 24 R 2 VCH 2 OR 24 , - CH 2 NR 24 R 25 , -OCOR 24 or -CO 2 R 24 , or R 19 and R 20 , R 20 and R 21 or R 21 and R 22 together form a bridge -OCH 2 O-;
  • R 24 and R 25 independently are hydrogen, -COR 26 , -SO 2 R 26 , lower alkyl, aryl or aryl-lower alkyl;
  • R 26 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 23 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 3a , R 3b , R 4a and R 4b independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 24a , -NR 24a R 25a , lower alkyl, aryl, aryl-lower alkyl, SCF 3 , -SR 24a , -CHF 2 2 ,, -O v_/Cv_#H ⁇ ⁇ F 22 ,, -CONR 24a R 25a , -CH 2 CONR 24a R 25a , -OCH 22 CCOONNRR 44aa RR 2255aa ,, --CCHH 22 OORR 2244aa ,, --CCHH 22 IN,R ⁇ 24a ,R ⁇ 25a ,, --OCO.RX 24a U o,r -- W CO 22 .RX 24a - , wherein R 2 a and R 25a independently are hydrogen
  • R 26a is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 3a and R 3b , R 4a and R 4b or R 3a and R 4b together form a bridge -(CH 2 ) r , wherein
  • i 1 , 2, 3 or 4;
  • a, b, c and d independently are 0, 1 , 2, 3 or 4;
  • e, f, p and q independently are 0 or 1 ;
  • R 5a and R 5b independently are hydrogen, lower alkyl, -(CH 2 ) k -OH, -(CH 2 ) k - NR 6a R 6b , aryl or aryl-lower alkyl;
  • k is 2, 3 or 4;
  • R 6a and R 6b independently are hydrogen, lower alkyl or aryl-lower alkyl
  • K preferably representing — (CH 2 ) b -0— (CH 2 ) d , (CH2 j_ CH - CH _ (CH2)d
  • r and s independently are 1 or 2;
  • Q' is -NR 36 -, -O- or -S-;
  • R 27 , R 28 , R 32 , R 33 , R 34 and R 35 are independently hydrogen, halogen, -CN, -CF 3 , -OCF 3> _O(CH 2 ) y CF 3 , -NO 2 , -OR 29 , -NR 29 R 30 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 29 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2> -OSO 2 R 29 , -OSO 2 CF 3 , -CONR 29 R 30 , -(CH 2 ) y CONR 29 R 30 , -O(CH 2 ) y CONR 29 R 30 , -(CH 2 ) y OR 29 , -(CH 2 ) y NR 29 R 30 , -OCOR 29 , -CO 2 R 29; or R 27 and R 28 , R 32 and R 33 ,
  • R 27 and R 28 preferably independently representing hydrogen, halogen,-CF 3 , -OCF 3 , -OCH 2 CF 3 , -OR 29 , lower alkyl, aryl or aryl-lower alkyl, or together forming a bridge -OCH 2 O-;
  • y is 1 , 2, 3 or 4;
  • R 29 and R 30 independently are hydrogen, -COR 31 , -SO 2 R 31 , lower alkyl, aryl or aryl-lower alkyl;
  • R 31 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 36 and R 39 independently are hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 38 is hydrogen, -OR 40 , -NR 40 R 41 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 40 , -CHF 2 , - OCHF 2 , -OCF 2 CHF 2 , -CONR 40 R 41 , -(CH 2 ) X CONR 40 R 41 , -O(CH 2 ) X CONR 40 R 41 , -(CH 2 ) x OR 40 , -(CH 2 ) X NR 40 R 41 , -OCOR 40 or -CO 2 R 40 ; x is 1 , 2, 3 or 4;
  • R 40 and R 41 independently are hydrogen, -COR 42 , -SO 2 R 42 , lower alkyl, aryl or aryl-lower alkyl;
  • R 42 is hydrogen, lower alkyl, aryl or aryl-lower alkyl.
  • R 1 and R 2 independently are hydrogen or lower alkyl or together form a valence bond
  • R 3 and R 4 independently are hydrogen or lower alkyl
  • n 0, 1 , 2 or 3;
  • n 0 or 1 ;
  • R 5 is hydrogen, lower alkyl, aryl-lower alkyl or -OR 6 ;
  • R 6 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 7 is hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 11 , -NR 11 R 12 , lower alkyl, aryl, -SCF 3 , -SR 11 , -CHF 2 , -OCHF 2 , -OSO 2 R 11 , -CONR 11 R 12 , -CH 2 OR 11 , -CH 2 NR 11 R 12 ,
  • R 8 and R 9 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3> -NO 2 , -OR 11 , -NR 11 R 12 , lower alkyl, aryl, -SCF 3 , -SR 11 , -CHF 2) -OCHF 2 , -OSO 2 R 11 , -CONR 1 R 12 , -CH 2 OR 11 , -CH 2 NR 11 R 12 , -OCOR 11 , -CO 2 R 13 or -OSO 2 CF 3> or R 8 and R 9 together form a bridge -OCH 2 O- or - OCH 2 CH 2 O-;
  • R 11 and R 12 independently are hydrogen, -COR 13 , -SO 2 R 13 , lower alkyl or aryl;
  • R 13 is hydrogen, lower alkyl, aryl-lower alkyl or aryl
  • R 10 is hydrogen, lower alkyl, aryl-lower alkyl or aryl;
  • R 14 and R 15 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -O(CH 2 ),CF 3 , -NO 2 , -OR 16 , -NR 16 R 17 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 16 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -OSO 2 CF 3 , -CONR 16 R 17 , -(CH 2 ),CONR 16 R 17 , -O(CH 2 ),CONR 16 R 17 , -(CH 2 ),COR 16 , -(CH 2 ),COR 16 , -(CH 2 ),COR 16 , -(CH 2 ),OR 16 , -O(CH 2 ),OR 16 , -(CH 2 ),NR 16 R 17 , -0(CH 2 ),NR 16 R 17 , -
  • R 14 andR 15 preferably independently representing hydrogen, halogen, -CF 3 , -OCF 3 , -OR 16 , -NR 16 R 17 , lower alkyl, aryl, aryl-lower alkyl, -OSO 2 CF 3 , -CONR 6 R 17 , -CH 2 OR 16 , -CH 2 NR 16 R 17 , -OCOR 16 or -CO 2 R 18 ; or together forming a bridge -OCH 2 O-;
  • I is 1 , 2, 3 or 4;
  • R 16 and R 17 independently are hydrogen, -COR 18 , -SO 2 R 18 , lower alkyl, aryl, or R 16 and R 17 together form a cyclic alkyl bridge containing from 2 to 7 carbon atoms;
  • R 18 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • Q is -NR 23 -, -O- or -S-;
  • R 19 , R 20 , R 21 and R 22 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 24 , -NR 24 R 25 , lower alkyl, aryl, aryl-lower alkyl, SCF 3 , -SR 24 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -OSO 2 CF 3 , -CONR 24 R 25 , -CH 2 CONR 24 R 25 , -OCH 2 CONR 24 R 25 , -CH 2 OR 24 , -CH 2 NR 24 R 25 , -OCOR 24 or -CO 2 R 24 , or R 19 and R 20 , R 20 and R 21 or R 21 and R 22 together form a bridge -OCH 2 O-;
  • R 24 and R 25 independently are hydrogen, -COR 26 , -SO 2 R 26 , lower alkyl, aryl or aryl-lower alkyl;
  • R 26 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 23 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 3a , R 3 , R 4a and R 4b independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 24a , -NR 24a R 25a , lower alkyl, aryl, aryl-lower alkyl, SCF 3 , -SR 24a , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2, -OSO 2 CF 3 , -CONR 24a R 25a , -CH 2 CONR 24a R 25a , -OCH 2 CONR 24a R 25a , -CH 2 OR 24a , -CH 2 NR 24a R 25a , -OCOR 24a or -CO 2 R 24a ; wherein R 24a and R 25a independently are hydrogen, -COR 26a , -SO 2 R 26a , lower alkyl, aryl or ary
  • R 6a is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 3a and R 3b , R 4a and R 4b or R 3a and R 4b together form a bridge -(CH 2 ) r ;
  • i is 1 , 2, 3 or 4;
  • a, b, c and d independently are 0, 1 , 2, 3 or 4;
  • e, f and p independently are 0 or 1 ;
  • q 0,1 or 2;
  • R 5a and R 5b independently are hydrogen, lower alkyl, -(CH 2 ) k -OH, -(CH 2 ) k - NR 6a R 6 , aryl or aryl-lower alkyl;
  • k is 2, 3 or 4;
  • R 6a and R 6b independently are hydrogen, lower alkyl or aryl-lower alkyl
  • K preferably representing -(CH 2 )- -N- -O— (CH 2 ) 2 -N— (CH H 2' ⁇
  • r and s independently are 0, 1 or 2;
  • F' is >CR 38 - or >N
  • Q' is -NR 36 -, -O- or -S-;
  • R 27 , R 28 ,R 32 , R 33 , R 34 and R 35 are independently hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -O(CH 2 ) y CF 3 , -NO 2 , -OR 29 , -NR 29 R 30 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 29 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -OSO 2 R 29 , -OSO 2 CF 3 , -CONR 29 R 30 , -(CH 2 ) y CONR 29 R 30 , -O(CH 2 ) y CONR 29 R 30 , -(CH 2 ) y OR 29 , -(CH 2 ) y NR 9 R 30 , -OCOR 29 or -CO 2 R 29 ;
  • R 27 and R 28 , R 3 and R 33 , R 33 and R M or R ⁇ and R 35 together form a bridge -OCH 2 O-;
  • R 27 and R 28 preferably independently representing hydrogen; halogen such as -Cl or -F; -CF 3 ; -OCF 3 . -OCHF 2 ; -OCH 2 CF 3 ; -OR 29 wherein R 29 is hydrogen or lower alkyl; lower alkyl such as methyl, isopropyl or tert-butyl; lower alkylthio; -SCF 3 ; -CH 2 OH; -COO-lower alkyl; aryl or -CONH 2 ; or together forming a bridge -OCH 2 O-;
  • y is 1 , 2, 3 or 4;
  • R 29 and R 30 independently are hydrogen, -COR 31 , -SO 2 R 31 , lower alkyl, aryl or aryl-lower alkyl;
  • R 31 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 36 and R 39 independently are hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 38 is hydrogen, -OR 40 , -NR 40 R 41 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 40 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -CONR 40 R 41 , -(CH 2 ) X CONR 40 R 41 , -O(CH 2 ) X CONR 40 R 41 , -(CH 2 ) x OR 40 , -(CH 2 ) X NR 40 R 41 , -OCOR 40 or -CO 2 R 40 ; wherein x is 1 , 2, 3 or 4;
  • R 40 and R 41 independently are hydrogen, -COR 42 , -SO 2 R 42 , lower alkyl, aryl or aryl-lower alkyl;
  • R 42 is hydrogen, lower alkyl, aryl or aryl-lower alkyl.
  • Preferred specific compounds represented by the formulae VI and VII are the following:
  • Especially preferred according to the present invention are the following compounds which show a particularly high affinity to the human giucagon receptor:
  • the compounds of the present invention may have one or more asymmetric centres and it is intended that any optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof are included in the scope of the invention.
  • one or more carbon-carbon or carbon-nitrogen double bonds may be present in the compounds which brings about geometric isomers. It is intended that any geometric isomers, as separated, pure or partially purified geometric isomers or mixtures thereof are included in the scope of the invention.
  • the compounds of the present invention may exist in different tautomeric forms, eg the following tautomeric forms:
  • any tautomeric forms which the compounds are able to form are included in the scope of the present invention. Owing to their efficacy in antagonizing the giucagon receptor the present compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases.
  • the present compounds may be applicable for the treatment of hyperglycemia associated with diabetes of any cause or associated with other diseases and conditions, eg impaired glucose tolerance, insulin resistance syndromes, syndrome X, type I diabetes, type II diabetes, hyperlipidemia, dyslipidemia, hypertriglyceridemia, glucagonomas, acute pancreatitis, cardiovascular diseases, cardiac hypertrophy, gastrointestinal disorders, diabetes as a consequence of obesity etc.
  • diseases and conditions eg impaired glucose tolerance, insulin resistance syndromes, syndrome X, type I diabetes, type II diabetes, hyperlipidemia, dyslipidemia, hypertriglyceridemia, glucagonomas, acute pancreatitis, cardiovascular diseases, cardiac hypertrophy, gastrointestinal disorders, diabetes as a consequence of obesity etc.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising, as an active ingredient, at least one compound according to the present invention together with one or more pharmaceutically acceptable carriers or excipients.
  • the present invention furthermore relates to methods of treating type I or type II diabetes or hyperglycemia which methods comprise administering to a subject in need thereof an effective amount of a compound according to the invention.
  • the present invention relates to a method of lowering blood glucose in a mammal, comprising administering to said mammal an effective amount of a compound according to the invention.
  • the present invention is also concerned with the use of a compound according to the invention for the manufacture of a medicament for treating type I or type II diabetes or hyperglycemia, or for lowering blood glucose in a mammal.
  • Pharmaceutical formulations and administration methods are also concerned with the use of a compound according to the invention for the manufacture of a medicament for treating type I or type II diabetes or hyperglycemia, or for lowering blood glucose in a mammal.
  • the compounds according to the invention may be administered for therapy by any suitable route including oral, rectal, nasal, pul- monal, topical (including buccal and sublingual), transdermal, vaginal and parenteral (including subcutaneous, intramuscular, intravenous and intradermal), the oral route being preferred. It will be appreciated that the preferred route will vary with the condition and age of the recipient, the nature of the condition to be treated, and the chosen active ingredient.
  • a typical dosage is in the range of from 0.05 to about 1000 mg, preferably of from about 0.1 to about 500 mg, such as of from about 0.5 mg to about 250 mg for administration one or more times per day such as 1 to 3 times per day. It should be understood that the exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated as well as other factors evident to those skilled in the art.
  • formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art.
  • parenteral routes such as intravenous, intrathecal, intramuscular and similar administration
  • typically doses are on the order of about 1/2 the dose employed for oral administration.
  • the compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof.
  • One example is an acid addition salt of a compound having the utility of a free base.
  • a compound of formula I contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of formula I with a chemical equivalent of a pharmaceutically acceptable acid, for example, inorganic and organic acids, for example: maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bis- methylene salicylic, methanesulfonic, ethanedisulfonic, acetic, oxalic, propionic, tartaric, sali- cylic, citric, pyruvic, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benz
  • the compounds of the invention may be administered alone or in combination with pharma- ceutically acceptable carriers, in either single or multiple doses.
  • solutions of the novel compounds of formula I in sterile aqueous solution, aqueous propylene glycol or sesame or peanut oil may be employed.
  • aqueous solutions should be suitable buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents.
  • solid carriers are lactose, terra alba, sucrose, cy- clodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose.
  • liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene or water.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • the pharmaceutical compositions formed by combining the novel compounds of formula I and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration.
  • the formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. These formulations may be in the form of powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oii liquid emulsion.
  • the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g.
  • the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • a typical tablet which may be prepared by conventional tabletting techniques may contain:
  • Active compound (as free compound or salt 100 mg thereof)
  • the preparation may contain a compound of formula I dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application.
  • a liquid carrier in particular an aqueous carrier
  • the carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
  • the pharmaceutical composition of the invention may comprise a compound of formula I combined with one or more other pharmacologically active compounds, e.g. an an- tidiabetic or other pharmacologically active material, including compounds for the treatment and/or prophylaxis of insulin resistance and diseases wherein insulin resistance is the pato- physiological mechanism.
  • Suitable antidiabetics comprise insulin, GLP-1 derivatives such as those disclosed in WO 98/08871 (Novo Nordisk A S) which is incorporated herein by refer- ence as well as orally active hypoglycaemic agents such as sulphonylureas, e.g. glibencla- mide and glipizide; biguanides, e.g.
  • metformin metformin
  • benzoic acid derivatives e.g. repaglinide
  • thiazolidinediones e.g. troglitazone and ciglitazone, as well as PPAR and RXR agonists.
  • Giucagon Binding Assay (I) Binding of compounds to the giucagon receptor was determined in a competition binding assay using the cloned human giucagon receptor.
  • antagonism was determined as the ability of the compounds to inhibit the amount of cAMP formed in the presence of 5 nM giucagon.
  • antagonism was determined in a functional assay, measured as the ability of the compounds to right-shift the giucagon dose-response curve. Using at least 3 different antagonist concentrations, the K, was calculated from a Schild plot. Receptor binding was assayed using cloned human receptor (Lok et al, Gene 140, 203-209 (1994)). The receptor inserted in the pLJ6' expression vector using EcoRI/SSt1 restriction sites (Lok et al) was expressed in a baby hamster kidney cell line (A3 BHK 570-25). Clones were selected in the presence of 0.5 mg/ml G-418 and were shown to be stable for more than 40 passages. The « ⁇ , was shown to be 0.1 nM.
  • Plasma membranes were prepared by growing cells to confluence, detaching them from the surface and resuspending the cells in cold buffer (10 mM tris/HCI), pH 7.4 containing 30 mM NaCl, 1 mM dithiothreitol, 5 mg/l leupeptin (Sigma), 5 mg/l pepstatin (Sigma), 100 mg/l baci- tracin (Sigma) and 15 mg/l recombinant aprotinin (Novo Nordisk)), homogenization by two 10-s bursts using a Polytron PT 10-35 homogenizer (Kinematica), and centrifugation upon a layer of 41 w/v% sucrose at 95.000 * g for 75 min. The white band located between the two layers was diluted in buffer and centrifuged at 40.000 * g for 45 min. The precipitate containing the plasma membranes was suspended in buffer and stored at -80°C until required.
  • Giucagon was iodinated according to the chloramine T method (Hunter and Greenwood, Na- ture 194, 495 (1962)) and purified using anion exchange chromatography (J ⁇ rgensen et al, Hormone and Metab. Res. 4, 223-224 (1972). The specific activity was 460 ⁇ Ci/ ⁇ g on day of iodination. Tracer was stored at -18°C in aliquots and were used immediately after thawing.
  • Binding assays were carried out in triplicate in filter microtiter plates (MADV N65, Millipore).
  • the buffer used in this assay was 25 mM HEPES pH 7.4 containing 0.1% human serum albumin (Sigma, grade V).
  • Giucagon was dissolved in 0.05 M HCI, added equal amounts(w/w) of HSA and freeze-dried. On the day of use, it was dissolved in water and diluted in buffer to the desired concentrations. 175 ⁇ l of sample (giucagon or test compounds) was added to each well. Tracer (50.000 cpm) was diluted in buffer and 15 ⁇ l was added to each well. 0.5 ⁇ g freshly thawed plasma membrane protein diluted in buffer was then added in 15 ⁇ l to each well.
  • the functional assay was carried out in 96 well microtiter plates (tissue culture plates, Nunc).
  • the resulting buffer concentrations in the assay were 50 mM tris/HCI, 1 mM EGTA, 1.5 mM MgSO 4 , 1.7 mM ATP, 20 ⁇ M GTP, 2 mM IBMX, 0.02% tween-20 and 0.1% HSA.
  • pH was 7.4 Giucagon and proposed antagonist were added in 35 ⁇ l diluted in 50 mM tris/HCI, 1 mM EGTA, 1.85 mM MgSO 4 , 0.0222 % tween-20 and 0.111 % HSA, pH 7.4.
  • the total assay volume was 140 ⁇ l.
  • the assay was incubated for 2 hours at 37°C with continuous shaking. Reaction was terminated by addition of 25 ⁇ l 0.5 N HCI.
  • cAMP was measured by the use of a scintillation proximity kit (Amersham).
  • Giucagon Binding Assay (lh Receptor binding was assayed using the cloned human receptor (Lok et al, Gene 140, 203- 209 (1994)). The receptor inserted in the pLJ6' expression vector using EcoRI/SSt1 restriction sites (Lok et al) was expressed in a baby hamster kidney cell line (A3 BHK 570-25). Clones were selected in the presence of 0.5 mg/ml G-418 and were shown to be stable for more than 40 passages. The Kd was shown to be 0.1 nM.
  • Plasma membranes were prepared by growing cells to confluence, detaching them from the surface and resuspending the cells in cold buffer (10 mM tris/HCI), pH 7.4 containing 30 mM NaCl, 1 mM dithiothreitol, 5 mg/l leupeptin Sigma), 5 mg/l pepstatin (Sigma), 100 mg/l baci- tracin (Sigma) and 15 mg/l recombinant aprotinin (Novo Nordisk)), homogenization by two 10-s bursts using a Polytron PT 10-35 homogenizer (Kinematica), and centrifugation. The ho- mogenate was resuspended and centrifuged again. The final precipitate containing the plasma membranes was suspended in buffer and stored at -80 C C until required.
  • cold buffer 10 mM tris/HCI
  • pH 7.4 containing 30 mM NaCl, 1 mM dithiothreitol, 5 mg/l le
  • Binding assays were carried out in duplicate in polypropylene tubes or microtiter plates.
  • the buffer used in this assay was 25 mM HEPES pH 7.4 containing 0.1 % bovine serum albumin
  • the functional assay determined the ability of the compounds to antagonize glucagon- stimulated formation of cAMP in a whole-cell assay.
  • the assay was carried out in borosilicate glass 12 x 75 tubes.
  • the buffer concentrations in the assay were 10 mM HEPES, 1 mM EGTA, 1.4 mM MgCI 2t 0.1 mM IBMX, 30 mM NaCl, 4.7 mM KCI, 2.5 mM NaH 2 PO 4 , 3mM glucose and 0.2% BSA.
  • the pH was 7.4. Loose whole cells (0.5 ml, 10 6 /ml) were pretreated with various concentrations of compounds for 10 min at 37°C, then challenged with giucagon for 20 min.
  • the compounds of general formula I may be prepared according to one embodiment of the invention, the alkylidene hydrazides of general formula II, as indicated in Scheme I, that is, by converting an ester of a carboxylic acid, for example, an aromatic acid to a hydrazide derivative and further reacting that product compound with a substituted aldehyde or ketone to yield a substituted alkylidene hydrazide.
  • HN-N r— (CH 2 ) n — B-(K)— D
  • A, B, K, D, m, n and R 4 are as defined for formula I and R a is lower alkyl.
  • the reactions are performed between 0°C to 130°C, preferably between 20°C to 100°C, most preferably at or about the reflux temperature of the solvent.
  • the reactions are preferably con- ducted under an inert atmosphere such as N 2 or Ar.
  • the solvent may be removed by concentration at atmospheric or reduced pressure.
  • the product can be further purified by either recrystallization from a solvent such as ethyl alcohol, methyl alcohol, isopropyl alcohol, toluene, xylene, hexane, tetrahydrofuran, diethyl ether, dibutyl ether, water or a mixture of two or more of the above.
  • the product can be purified by column chromatography using dichloromethane/methanol or chloroform/methanol or isopropyl alcohol as eluent.
  • the corresponding fractions are concentrated either at atmospheric pressure or in vacuo to provide the pure aroyl hydrazide.
  • aromatic acid hydrazides The methyl or ethyl ester of the corresponding aromatic acid, such as for example a substituted benzoic acid ester, is dissolved in ethanol and hydrazine (5 eq) is added. The reaction is refluxed overnight under nitrogen. Upon cooling the substituted hydrazide derivative usually precipitates. After filtration the product is usually recrystallized from hot methanol, ethanol or isopropyl alcohol. In cases where the hydrazide does not precipitate, the reaction is concen- trated under vacuo and chromatographed over silica gel using dichloromethane/methanol as the eluent. Specific examples illustrating the preparation of aromatic hydrazides are provided below.
  • step D Preparation of 2.3-Dichloro-4-hydroxybenzoic acid hydrazide and 2.5-dichloro-4- hydroxybenzoic acid hydrazide
  • 2,5-dichloro-4-hydroxybenzoic acid hydrazide was prepared in a similar way starting from 2,5-dichloro-4-hydroxybenzoate.
  • the product was purified via silica gel column chromatography using CH2Cl2/MeOH ( 95/5 to 80/20) to afford the title compound.
  • Methyl-4-hydroxybenzoate (35.5 g, 0.233 mol) was dissolved in 200 mL of warm (65 °C) acetic acid. A solution of iodine monochloride (37.8 g, 0.233 mol) in 50 mL of acetic acid was added slowly (40 minutes) to the methyl-4-hydroxybenzoate solution, while maintaining a temperature of 65 °C and vigorous stirring. The product crystallizes from solution upon cooling to room temperature and standing overnight. The crystals were collected on a filter, washed with water, then dried under vacuum. Methyl-4-hydroxy-3-iodobenzoate was obtained as white crystals (28.6 g, 44%).
  • Methyl-4-hydroxy-3-iodobenzoate (2.00 g, 7.2 mmol) was dissolved into 5 mL of dry DMF. Copper(l) cyanide (0.72 g, 8.0 mmol) and a small crystal of sodium cyanide was added. The mixture was flushed with nitrogen, placed in an oil heating bath (100-110 °C), and stirred overnight. TLC indicated nearly complete reaction. The mixture was cooled and the solids removed by filtration. The solids were extracted with DMF (3 mL). The filtrate and washings were taken up in 100 mL of ethyl acetate, then washed with 3 portions of saturated sodium chloride solution.
  • Methyl-3-cyano-4-hydroxybenzoate (2.71 g, 15.3 mmol) was dissolved in 50 mL of THF. The solution was chilled in an ice bath, and 2.0M potassium hydroxide (17 mL, 34 mmol) was added dropwise. The resulting mixture was stirred at room temperature overnight. TLC indicated complete reaction. The THF was removed by rotary evaporation. The aqueous re- sidue was acidified with aqueous trifluoroacetic acid and purified by reverse-phase HPLC (C- 18, 0.1 % TFA in water and acetonitrile). 3-Cyano-4-hydroxybenzoic acid was obtained as a white powder (2.1g, 84%) after lyophilization.
  • Step E The Boc-hydrazide (1.8g, 6.5 mmol) was suspended in 50 mL of chloroform and cooled in an ice-bath. Trifluoroacetic acid was added with stirring, and the resulting solution stood for 4 hours at 0 °C. TLC indicated complete reaction. Solvent and excess TFA were removed by rotary evaporation. The remaining oil was purified by reverse-phase liquid chromatography (Aquasil C-18 column, water/acetonitrile/0.1 % TFA). The title compound was obtained as a white solid (0.24 g, 13%).
  • Step A Silver nitrate (17 g, 0.1 mol) was dissolved in water (10 mL) and treated with 1 N NaOH (300 mL, 0.3 mol). The brown precipitate which was formed was stirred for 30 minutes and the supernatant was decanted. The brown silver oxide was washed with additional volumes of water (3x). To the silver oxide above was added 1N NaOH (150 mL) and 4-hydroxynaphthaldehyde (1 g, 6 mmol)). The mixture was heated to 70 °C for 10 minutes after which additional amounts of 4-hydroxynaphthaldehyde (5.5 g, 32 mmol) was added in portions. The mixture was kept at 80 °C for 16 hours. TLC analysis indicated incomplete conversion.
  • the ether-linked aldehydes may be prepared by 0-alkylation of the corresponding phenolic compounds using various electrophilic alkylating agents that introduce the -(K) m -D moiety as defined above in a reaction generally known as Williamson ether synthesis (H. Feuer, J. Hooz in The Chemistry of the Ether Linkage, S. Patai Ed., Wiley, New York 1967, p. 446-460).
  • Lx is a leaving group such as -Cl, -Br, -I, -OSO 2 CH 3 , -OSO 2 p-tolyl or -OSO 2 CF 3 ;
  • an ether-substituted aryl-aldehyde can be prepared by stirring hy- droxybenzaldehydes or hydroxynaphthaldehydes in an organic solvent such as acetone, meth- ylethyl ketone, dimethylformamide, dioxane, tetrahydrofuran, toluene, ethylene glycol dimethyl ether, sulfolane, diethylether, water or a compatible mixture of two or more of the above solvents with an equimolar amount of an alkyl halide or an aryl-lower alkyl halide and in the pres- ence of 1 to 15 equivalents (preferably 1 to 5 equivalents) of a base such as sodium hydride, potassium hydride, sodium or potassium methoxide, ethoxide or tej -butoxide, sodium, potassium or cesium carbonate, potassium or cesium fluoride, sodium or potassium hydroxide or organic bases
  • the reaction can be performed at 0°C to 150°C, preferably at 20°C to 100°C and preferably in an inert atmosphere of N 2 or Ar.
  • the reaction is complete the mixture is filtered, concentrated in vacuo and the resulting product optionally purified by column chromatography on silica gel using ethyl acetate/hexane as eluent.
  • the compound can also (when appropriate) be purified by recrystallization from a suitable solvent such as ethyl alcohol, ethyl acetate, isopropyl alcohol, water, hexane, toluene or their compatible mixture. Specific examples illustrating the preparation of ether-substituted aryl-aldehydes are provided below.
  • the crude syrup was heated neat in an oil bath at 200 °C for 6 h.
  • the crude material was dissolved in chloroform and filtered through a pack of silica gel.
  • the crude product (yield 72%) was used as is in the next step for O-alkylation.
  • a small portion was purified using prep-TLC to give a pure sample of 3-allyl-4-hydroxy-5-methoxy-benzaldehyde.
  • step D This type of aldehydes can be coupled to hydrazides using the methodology as described in step D to give a compound of formula IXa.
  • these compounds can undergo rearrangement by treatment with base as described below (step C), followed by coupling to a hydrazide (step D) to give a compound of formula IXb.
  • the resulting carbonyl compounds are treated with the corresponding acylhydrazide in a solvent.
  • the solvent may be one of the following: ethyl alcohol, methyl alcohol, isopropyl alcohol, tert-butyl alcohol, dioxane, tetrahydrofuran, toluene, chlorobenzene, anisole, benzene, chloroform, dichloromethane, DMSO, acetic acid, water or a compatible mixture of two or more of the above solvents.
  • a catalyst such as acetic acid can be added.
  • a dehydrating reagent such as triethylorthoformate can also be added to the reaction mixture.
  • the reaction is performed by stirring the reaction mixture preferably under an inert atmosphere of N 2 or Ar at temperatures between 0°C to 140°C, preferably between 10°C to 80°C.
  • the product simply crystallizes out when the reaction is completed and is isolated by suction filtration. It can be further recrystallized if necessary from a solvent such as the above described reaction sol- vents.
  • the product can also be isolated by concentration of the reaction mixture in vacuo, followed by column chromatography on silica gel using a solvent system such as chloroform/methanol or dichloromethane/methanol or chloroform/ethyl acetate to give a compound of formula IXb.
  • the acylhydrazides are treated with the corresponding carbonyl compounds, such as aldehydes or ketones, in a solvent.
  • the solvent may be one of the following: ethyl alcohol, methyl alcohol, isopropyl alcohol, te/ ⁇ f-butyl alcohol, dioxane, tetrahydrofuran, toluene, chlorobenzene, anisole, benzene, chloroform, dichloromethane, DMSO, acetic acid, water or a compatible mixture of two or more of the above solvents.
  • the reaction is performed by stirring the reaction mixture preferably under an inert atmosphere of N 2 or Ar at temperatures between 0°C to 140°C, preferably between 10°C to 80°C.
  • the product simply crystallizes out when the reaction is completed and is isolated by suction filtration. It can be further recrystal- lized if necessary from a solvent such as the above described reaction solvents.
  • the product can also be isolated by concentration of the reaction mixture in vacuo. followed by column chromatography on silica gel using a solvent system such as chloroform/-methanol or dichloromethane/methanol or chloroform/ethyl acetate. The product is isolated by concentration in vacuo of the appropriate fractions. Specific examples illustrating the preparation of compounds according to the invention are provided below. EXAMPLE 6:

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des composés non peptidiques comprenant un motif hydrazide central ainsi que leurs procédés de synthèse. Les composés ont un effet antagoniste sur l'action de l'hormone peptidique glucagon.
PCT/DK1998/000287 1997-07-01 1998-06-30 Antagonistes/agonistes inverses du glucagon WO1999001423A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BR9810378-4A BR9810378A (pt) 1997-07-01 1998-06-30 Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
JP50616099A JP2003514508A (ja) 1997-07-01 1998-06-30 グルカゴン拮抗剤／逆作用剤
CA002294046A CA2294046A1 (fr) 1997-07-01 1998-06-30 Antagonistes/agonistes inverses du glucagon
AU79083/98A AU749271B2 (en) 1997-07-01 1998-06-30 Glucagon antagonists/inverse agonists
HU0002373A HUP0002373A3 (en) 1997-07-01 1998-07-01 Glucagon antagonists/inverse agonists
EP98929244A EP0994848A1 (fr) 1997-07-01 1998-07-01 Antagonistes/agonistes inverses du glucagon
IL13337798A IL133377A0 (en) 1997-07-01 1998-07-01 Glucagon antagonists/inverse agonists
NO996550A NO996550L (no) 1997-07-01 1999-12-29 Glukagonantagonister/inversagonister

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88678597A 1997-07-01 1997-07-01
US3251698A 1998-02-27 1998-02-27
US08/886,785 1998-02-27
US09/032,516 1998-02-27

Publications (2)

Publication Number Publication Date
WO1999001423A1 true WO1999001423A1 (fr) 1999-01-14
WO1999001423A8 WO1999001423A8 (fr) 1999-05-14

Family

ID=26708528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1998/000287 WO1999001423A1 (fr) 1997-07-01 1998-06-30 Antagonistes/agonistes inverses du glucagon

Country Status (11)

Country Link
EP (1) EP0994848A1 (fr)
JP (1) JP2003514508A (fr)
KR (1) KR20010020590A (fr)
CN (1) CN1267281A (fr)
AU (1) AU749271B2 (fr)
BR (1) BR9810378A (fr)
HU (1) HUP0002373A3 (fr)
IL (1) IL133377A0 (fr)
NO (1) NO996550L (fr)
PL (1) PL337781A1 (fr)
WO (1) WO1999001423A1 (fr)

Cited By (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039088A1 (fr) * 1998-12-23 2000-07-06 Novo Nordisk A/S Antagonistes de glucagon/agonistes inverses
WO2000042026A1 (fr) * 1999-01-15 2000-07-20 Novo Nordisk A/S Agonistes non peptidiques de glp-1
WO2000069810A1 (fr) * 1999-05-17 2000-11-23 Novo Nordisk A/S Antagonistes/agonistes inverses de glucagon
WO2001055107A2 (fr) * 2000-01-28 2001-08-02 Melacure Therapeutics Ab Nouveaux amines et amides aromatiques agissant sur les recepteurs de la melanocortine
WO2002000612A1 (fr) * 2000-06-23 2002-01-03 Novo Nordisk A/S Antagonistes/agonistes inverses du glucagon
WO2002040446A1 (fr) * 2000-11-17 2002-05-23 Novo Nordisk A/S Antagonistes/agonistes inverses du glucagon
WO2002040444A1 (fr) * 2000-11-17 2002-05-23 Novo Nordisk A/S Antagonistes/agonistes inverses de glucagon
WO2002040445A1 (fr) * 2000-11-17 2002-05-23 Novo Nordisk A/S Agonistes de glucagon/antagonistes inverses
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
WO2003031432A1 (fr) 2001-10-12 2003-04-17 Novo Nordisk A/S Nouvelles piperidines substituees
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2003055482A1 (fr) 2001-12-21 2003-07-10 Novo Nordisk A/S Derives amide utiles en tant qu'activateurs de la glucokinase
WO2003078386A1 (fr) * 2002-03-19 2003-09-25 Unisearch Limited Derives de naphthyl(thio)semicarbazone et leur utilisation therapeutique
WO2003097031A1 (fr) * 2002-05-22 2003-11-27 Sanwa Kagaku Kenkyusho Co., Ltd. Medicament contre l'obesite a base de methylidene hydrazide
WO2004002481A1 (fr) 2002-06-27 2004-01-08 Novo Nordisk A/S Activateurs de la glycokinase
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
JP2005060385A (ja) * 2003-07-31 2005-03-10 Dainippon Pharmaceut Co Ltd ２−フランカルボン酸ヒドラジド化合物からなる医薬
WO2005030797A2 (fr) 2003-09-30 2005-04-07 Novo Nordisk A/S Nouveaux agonistes du recepteur de la melanocortine
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
US6989397B1 (en) 1999-09-02 2006-01-24 University Of Queensland Iron chelators and uses thereof
EP1625847A1 (fr) 2001-07-06 2006-02-15 Merck & Co., Inc. Composition pharmaceutique comprenant un tetrahydrotriazolo[4,3-a]pyrazine
WO2006053906A1 (fr) 2004-11-22 2006-05-26 Novo Nordisk A/S Formulations solubles stables contenant de l'insuline et un sel de protamine
WO2006058923A1 (fr) 2004-12-03 2006-06-08 Novo Nordisk A/S Composés hétéroaromatiques activants de glucokinase
WO2006072881A1 (fr) 2005-01-10 2006-07-13 Cortendo Invest Ab Procedes et compositions pour le traitement du diabete, du syndrome metabolique et d'autres conditions
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
WO2006082204A1 (fr) 2005-02-02 2006-08-10 Novo Nordisk A/S Derives d'insuline
EP1741446A2 (fr) 2000-01-21 2007-01-10 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
WO2007003581A1 (fr) 2005-06-30 2007-01-11 Novo Nordisk A/S Acides phénoxyacétiques en tant qu'activateurs de rapp-delta
WO2007006814A1 (fr) 2005-07-14 2007-01-18 Novo Nordisk A/S Activateurs de l'uree glucokinase
WO2007015805A1 (fr) 2005-07-20 2007-02-08 Eli Lilly And Company Composés joints en position 1-amino
WO2007033266A2 (fr) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Administration d'inhibiteurs de dipeptidyl peptidase
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
EP1801098A1 (fr) 2005-12-16 2007-06-27 Merck Sante Dérivés de 2-Adamantylurea comme inhibiteurs de 11B-HSD1
WO2007110364A1 (fr) 2006-03-28 2007-10-04 High Point Pharmaceuticals, Llc Benzothiazoles presentant une activité sur le récepteur h3 de l'histamine
WO2007137968A1 (fr) 2006-05-29 2007-12-06 High Point Pharmaceuticals, Llc Benzodioxolylcyclopropylpipérazinylpyridazines
WO2008059025A1 (fr) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Nouvelles 2-(2-hydroxyphényl) benzothiadiazines utilisées pour traiter l'obésité et le diabète
US7381736B2 (en) 2004-09-02 2008-06-03 Metabasis Therapeutics, Inc. Thiazole and thiadiazole inhibitors of tyrosine phosphatases
WO2008074384A1 (fr) 2006-12-21 2008-06-26 Merck Patent Gmbh Dérivés de 2-adamantyle-butyramide en tant qu'inhibiteurs sélectifs de 11βêta-hsd1
WO2008084044A1 (fr) 2007-01-11 2008-07-17 Novo Nordisk A/S Activateurs de l'urée glucokinase
US7514452B2 (en) 2002-02-01 2009-04-07 Dainippon Pharmaceutical Co., Ltd 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
US7598398B2 (en) 2005-10-13 2009-10-06 Merck & Co., Inc. Acyl indoles, compositions containing such compounds and methods of use
EP2107908A2 (fr) * 2007-02-02 2009-10-14 Redpoint Bio Corporation Utilisation d'un inhibiteur de trpm5 pour réguler une sécrétion d'insuline et de glp-1
EP2110374A1 (fr) 2008-04-18 2009-10-21 Merck Sante Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR
WO2009150387A1 (fr) * 2008-06-13 2009-12-17 Sanofi-Aventis Derives de 2-oxo-alkyl-1-piperazin-2-one, leur preparation et leur application en therapeutique
FR2932482A1 (fr) * 2008-06-13 2009-12-18 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
US20100035932A1 (en) * 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
US7687534B2 (en) 2006-10-03 2010-03-30 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010056717A1 (fr) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Amines bicycliques substituées pour le traitement du diabète
WO2010059618A1 (fr) 2008-11-21 2010-05-27 High Point Pharmaceuticals, Llc Adamantylbenzamides
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2233470A1 (fr) 2005-07-04 2010-09-29 High Point Pharmaceuticals, LLC Antagonists du receptor histamine H3
EP2239012A2 (fr) 2003-04-11 2010-10-13 High Point Pharmaceuticals, LLC Utilisation pharmaceutique d'amides substitués
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
WO2011011508A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés d’oxazépine benzofusionnés en tant qu’inhibiteurs de la coenzyme-stéaroyle a delta-9 désaturase
WO2011019538A1 (fr) 2009-08-13 2011-02-17 Merck Sharp & Dohme Corp. Composés cyclopropyle substitués, compositions contenant de tels composés et procédés de traitement
EP2292653A1 (fr) 2005-02-02 2011-03-09 Novo Nordisk A/S Nouveaux dérivés d'insuline
WO2011028455A1 (fr) 2009-09-02 2011-03-10 Merck Sharp & Dohme Corp. Aminotétrahydropanes utilisés comme inhibiteurs de la dipeptyl peptidase-iv pour traiter ou prévenir le diabète
EP2298337A2 (fr) 2003-12-09 2011-03-23 Novo Nordisk A/S Régulation des préférences alimentaires en utilisant des agonistes du GLP-1
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
US7935713B2 (en) 2006-05-16 2011-05-03 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2316446A1 (fr) 2004-06-11 2011-05-04 Novo Nordisk A/S Remède contre l'obésité induite par les médicaments au moyen d'agonistes GLP-1
WO2011058193A1 (fr) 2009-11-16 2011-05-19 Mellitech Dérivés de [1,5]-diazocine
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2011097079A1 (fr) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase 1 régulant le signal d'apoptose
WO2011103256A1 (fr) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Aminotétrahydrothiopyranes substitués et dérivés de ceux-ci utilisés en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le cadre du traitement du diabète
WO2011104379A1 (fr) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides pour le traitement de l'obésité
WO2011104378A1 (fr) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides de traitement de l'obésité
WO2011117416A1 (fr) 2010-03-26 2011-09-29 Novo Nordisk A/S Nouveaux analogues du glucagon
EP2386540A1 (fr) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Nouveaux composés, leur utilisation et préparation
WO2011146358A1 (fr) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
WO2012024183A1 (fr) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Composés spiroxazolidinone
EP2444397A1 (fr) 2004-01-06 2012-04-25 Novo Nordisk A/S Hétéroaryl-urées et leur utilisation en tant qu'activateurs de glucokinase
WO2012130866A1 (fr) 2011-03-28 2012-10-04 Novo Nordisk A/S Nouveaux analogues de glucagon
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
WO2012164071A1 (fr) 2011-06-02 2012-12-06 Intervet International B.V. Dérivés d'imidazole
WO2013048916A1 (fr) 2011-09-30 2013-04-04 Merck Sharp & Dohme Corp. Composés de cyclopropyle substitués, compositions contenant ces composés et méthodes de traitement
WO2013068328A1 (fr) 2011-11-07 2013-05-16 Intervet International B.V. Composés d'acide bicyclo[2.2.2]octan-1-ylcarboxylique comme inhibiteurs de la dgat-1
WO2013068439A1 (fr) 2011-11-09 2013-05-16 Intervet International B.V. Composés 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazépine comme inhibiteurs de dgat1
US8507533B2 (en) 2011-02-08 2013-08-13 Pfizer Inc. Glucagon receptor modulators
WO2013122920A1 (fr) 2012-02-17 2013-08-22 Merck Sharp & Dohme Corp. Inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prévention du diabète
US8518947B2 (en) 2009-12-14 2013-08-27 Sanofi (Heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
WO2013155600A1 (fr) 2012-04-16 2013-10-24 Kaneq Pharma Dérivés de phosphonates aromatiques fusionnés utilisés comme précurseurs d'inhibiteurs de ptp-1b
US8580790B2 (en) 2009-12-14 2013-11-12 Sanofi (Heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
EP2676961A1 (fr) 2008-11-13 2013-12-25 Merck Sharp & Dohme Corporation Combinaison thérapeutique contenant des aminotetrahydropyrannes en tant qu'inhibiteurs de dipeptidyl peptidase-IV pour le traitement ou la prévention des diabètes
WO2014018350A1 (fr) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Traitement du diabète par administration d'inhibiteurs de dipeptidyl peptidase-iv
US8648073B2 (en) 2009-12-30 2014-02-11 Fochon Pharma, Inc. Certain dipeptidyl peptidase inhibitors
US8809342B2 (en) 2010-12-23 2014-08-19 Pfizer Inc. Glucagon receptor modulators
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
US8957062B2 (en) 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
US9006228B2 (en) 2011-06-16 2015-04-14 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
US9018224B2 (en) 2011-11-15 2015-04-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
US9029403B2 (en) 2011-11-10 2015-05-12 Memorial Sloan-Kettering Cancer Center Treatment of ovarian cancer with benzylidenebenzohydrazides
WO2015112465A1 (fr) 2014-01-24 2015-07-30 Merck Sharp & Dohme Corp. Dérivés d'isoquinoline utilisés comme inhibiteurs de mgat2
WO2015160678A1 (fr) 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Complexe de tannate de sitagliptine
US9198906B2 (en) 2006-10-02 2015-12-01 Cortendo Ab (Publ) Ketoconazole enantiomer in humans
WO2016065090A1 (fr) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonistes des récepteurs du glucagon et du glp-1
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
WO2017062334A1 (fr) 2015-10-05 2017-04-13 Merck Sharp & Dohme Corp. Conjugués anticorps-peptides ayant une activité agoniste au niveau des récepteurs au glucagon et au peptide-1 similaire au glucagon
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US9763940B2 (en) 2011-12-20 2017-09-19 Sanofi Therapeutic use of P75 receptor antagonists
US9867869B2 (en) 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
WO2018034918A1 (fr) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Composés utiles pour modifier les taux d'acides biliaires pour le traitement du diabète et de maladies cardiométaboliques.
WO2018034917A1 (fr) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Composés utiles pour modifier les taux d'acides biliaires pour le traitement du diabète et de maladies cardiométaboliques.
WO2018167194A1 (fr) 2017-03-15 2018-09-20 Novo Nordisk A/S Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
WO2019219714A1 (fr) 2018-05-15 2019-11-21 Novo Nordisk A/S Composés capables de se lier au récepteur de la mélanocortine 4
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
WO2020053414A1 (fr) 2018-09-14 2020-03-19 Novo Nordisk A/S Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4
WO2020074958A1 (fr) 2018-10-12 2020-04-16 Strongbridge Dublin Limited Lévokétoconazole pour le traitement de l'hyperplasie surrénale congénitale et de l'aldostéronisme primaire
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2020205688A1 (fr) 2019-04-04 2020-10-08 Merck Sharp & Dohme Corp. Inhibiteurs d'histone désacétylase -3 utiles pour le traitement du cancer, de l'inflammation, de maladies neurodégénératives et du diabète
EP3842449A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes d'oléfine agrafés du glucagon et récepteurs glp-1
EP3842061A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes triazoles agrafés des récepteurs du glucagon et du glp-1
EP3842060A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes lactames agrafés des récepteurs du glucagon et du glp-1

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004030987A1 (de) * 2004-06-26 2006-01-12 Merck Patent Gmbh Ortho-substituierte (3-Hydroxyphenyl)-essigsäure-benzyliden-hydrazide
CN104672144A (zh) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和硝基苯类gpr119激动剂、制备方法及其用途
CN104610157A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一类环丙基酰肼和卤代苯类结构的gpr119激动剂及其用途
CN104610150A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 含酰肼和腈基苯类结构的化合物、其制备方法及用途
CN104610156A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和腈基苯类gpr119激动剂、制备方法及其用途
CN104592121A (zh) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 含酰肼和硝基苯类结构的化合物、其制备方法及用途
CN104610151A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 含酰肼和烷氧苯类结构的化合物、其制备方法及用途
CN104557717A (zh) * 2015-02-13 2015-04-29 佛山市赛维斯医药科技有限公司 酰肼类gpr119激动剂、制备方法及其用途
CN104592120A (zh) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和甲氧苯类gpr119激动剂、制备方法及其用途
CN107151220B (zh) * 2015-10-19 2021-07-20 中国医学科学院药物研究所 含苄氧基苯基的酚类化合物、其制备方法及用途
CN110229056B (zh) * 2019-06-21 2022-11-08 天津科技大学 一种新型姜黄素类似物及其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3746703A (en) * 1971-07-01 1973-07-17 American Home Prod 2,6-dichlorobenzylidenehydrazides
US3836580A (en) * 1971-07-01 1974-09-17 American Home Prod 2,6-dichlorobenzylidenehydrazides
US3859281A (en) * 1971-07-01 1975-01-07 American Home Prod 2,6-dichlorobenzylidenehydrazides
US4334015A (en) * 1979-05-23 1982-06-08 Minnesota Mining And Manufacturing Company Imaging compositions
EP0451653A2 (fr) * 1990-04-11 1991-10-16 Bayer Ag Derivés de naphtalène
US5229038A (en) * 1990-09-12 1993-07-20 Fuji Photo Film Co., Ltd. Organic nonlinear optical material and method of converting the wavelength of light using said material
WO1997016442A1 (fr) * 1995-10-31 1997-05-09 Merck & Co., Inc. Pyrroles de pyridyle substitues, compositions contenant de tels composes et mode d'utilisation
US5728646A (en) * 1995-05-16 1998-03-17 Asahi Denka Kogyo Kabushiki Kaisha Heat-sensitive recording material

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3746703A (en) * 1971-07-01 1973-07-17 American Home Prod 2,6-dichlorobenzylidenehydrazides
US3836580A (en) * 1971-07-01 1974-09-17 American Home Prod 2,6-dichlorobenzylidenehydrazides
US3859281A (en) * 1971-07-01 1975-01-07 American Home Prod 2,6-dichlorobenzylidenehydrazides
US4334015A (en) * 1979-05-23 1982-06-08 Minnesota Mining And Manufacturing Company Imaging compositions
EP0451653A2 (fr) * 1990-04-11 1991-10-16 Bayer Ag Derivés de naphtalène
US5229038A (en) * 1990-09-12 1993-07-20 Fuji Photo Film Co., Ltd. Organic nonlinear optical material and method of converting the wavelength of light using said material
US5728646A (en) * 1995-05-16 1998-03-17 Asahi Denka Kogyo Kabushiki Kaisha Heat-sensitive recording material
WO1997016442A1 (fr) * 1995-10-31 1997-05-09 Merck & Co., Inc. Pyrroles de pyridyle substitues, compositions contenant de tels composes et mode d'utilisation

Cited By (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649641B2 (en) 1970-11-01 2003-11-18 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2000039088A1 (fr) * 1998-12-23 2000-07-06 Novo Nordisk A/S Antagonistes de glucagon/agonistes inverses
WO2000042026A1 (fr) * 1999-01-15 2000-07-20 Novo Nordisk A/S Agonistes non peptidiques de glp-1
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
JP2002544254A (ja) * 1999-05-17 2002-12-24 ノボ ノルディスク アクティーゼルスカブ グルカゴンアンタゴニスト／逆アゴニスト
WO2000069810A1 (fr) * 1999-05-17 2000-11-23 Novo Nordisk A/S Antagonistes/agonistes inverses de glucagon
US6875760B2 (en) 1999-05-17 2005-04-05 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US6989397B1 (en) 1999-09-02 2006-01-24 University Of Queensland Iron chelators and uses thereof
EP1743655A1 (fr) 2000-01-21 2007-01-17 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabétiques
EP1741446A2 (fr) 2000-01-21 2007-01-10 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
WO2001055107A3 (fr) * 2000-01-28 2002-01-17 Melacure Therapeutics Ab Nouveaux amines et amides aromatiques agissant sur les recepteurs de la melanocortine
WO2001055107A2 (fr) * 2000-01-28 2001-08-02 Melacure Therapeutics Ab Nouveaux amines et amides aromatiques agissant sur les recepteurs de la melanocortine
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6953812B2 (en) 2000-06-23 2005-10-11 Novo Nordisk, Inc. Glucagon antagonists/inverse agonists
WO2002000612A1 (fr) * 2000-06-23 2002-01-03 Novo Nordisk A/S Antagonistes/agonistes inverses du glucagon
WO2002040444A1 (fr) * 2000-11-17 2002-05-23 Novo Nordisk A/S Antagonistes/agonistes inverses de glucagon
WO2002040446A1 (fr) * 2000-11-17 2002-05-23 Novo Nordisk A/S Antagonistes/agonistes inverses du glucagon
WO2002040445A1 (fr) * 2000-11-17 2002-05-23 Novo Nordisk A/S Agonistes de glucagon/antagonistes inverses
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
EP1625847A1 (fr) 2001-07-06 2006-02-15 Merck & Co., Inc. Composition pharmaceutique comprenant un tetrahydrotriazolo[4,3-a]pyrazine
EP2226324A1 (fr) 2001-07-06 2010-09-08 Merck Sharp & Dohme Corp. Beta-amino tetrahydroimidazo(1,2-a)pyrazines et tetrahydrotriazolo(4,3-a)pyrazines pour une utilisation de traitement du diabete de type ii
EP2292232A1 (fr) 2001-07-06 2011-03-09 Merck Sharp & Dohme Corp. Beta-amino tetrahydroimidazo(1,2-A)pyrazines et tetrahydrotriazolo(4,3-A)pyrazines pour une utilisation de traitement du diabete de type II
EP2243776A1 (fr) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Piperidines substituées et leur utilisation dans le traitement de maladies liées au recepteur histaminique H3
WO2003031432A1 (fr) 2001-10-12 2003-04-17 Novo Nordisk A/S Nouvelles piperidines substituees
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
WO2003055482A1 (fr) 2001-12-21 2003-07-10 Novo Nordisk A/S Derives amide utiles en tant qu'activateurs de la glucokinase
EP2305648A1 (fr) 2001-12-21 2011-04-06 Novo Nordisk A/S Dérivés d'amide en tant qu'activateurs de la glucokinase
US7514452B2 (en) 2002-02-01 2009-04-07 Dainippon Pharmaceutical Co., Ltd 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
WO2003078386A1 (fr) * 2002-03-19 2003-09-25 Unisearch Limited Derives de naphthyl(thio)semicarbazone et leur utilisation therapeutique
WO2003097031A1 (fr) * 2002-05-22 2003-11-27 Sanwa Kagaku Kenkyusho Co., Ltd. Medicament contre l'obesite a base de methylidene hydrazide
JPWO2003097031A1 (ja) * 2002-05-22 2005-09-15 株式会社三和化学研究所 メチリデンヒドラジド化合物を有効成分とする、肥満の予防又は改善剤
US7081473B2 (en) 2002-05-22 2006-07-25 Sanwa Kagaku Kenkyusho Co., Ltd. Agent for preventing/ameliorating obesity comprising methylidene hydrizide compound as active ingredient
EP1506777A4 (fr) * 2002-05-22 2007-07-18 Sanwa Kagaku Kenkyusho Co Medicament contre l'obesite a base de methylidene hydrazide
EP1506777A1 (fr) * 2002-05-22 2005-02-16 Sanwa Kagaku Kenkyusho Co., Ltd. Medicament contre l'obesite a base de methylidene hydrazide
EP2471533A1 (fr) 2002-06-27 2012-07-04 Novo Nordisk A/S Dérivés d'aryle carbonyle en tant qu'agents thérapeutiques
WO2004002481A1 (fr) 2002-06-27 2004-01-08 Novo Nordisk A/S Activateurs de la glycokinase
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
EP2239012A2 (fr) 2003-04-11 2010-10-13 High Point Pharmaceuticals, LLC Utilisation pharmaceutique d'amides substitués
JP2005060385A (ja) * 2003-07-31 2005-03-10 Dainippon Pharmaceut Co Ltd ２−フランカルボン酸ヒドラジド化合物からなる医薬
WO2005030797A2 (fr) 2003-09-30 2005-04-07 Novo Nordisk A/S Nouveaux agonistes du recepteur de la melanocortine
EP2298337A2 (fr) 2003-12-09 2011-03-23 Novo Nordisk A/S Régulation des préférences alimentaires en utilisant des agonistes du GLP-1
EP2444397A1 (fr) 2004-01-06 2012-04-25 Novo Nordisk A/S Hétéroaryl-urées et leur utilisation en tant qu'activateurs de glucokinase
EP2316446A1 (fr) 2004-06-11 2011-05-04 Novo Nordisk A/S Remède contre l'obésité induite par les médicaments au moyen d'agonistes GLP-1
US7381736B2 (en) 2004-09-02 2008-06-03 Metabasis Therapeutics, Inc. Thiazole and thiadiazole inhibitors of tyrosine phosphatases
WO2006053906A1 (fr) 2004-11-22 2006-05-26 Novo Nordisk A/S Formulations solubles stables contenant de l'insuline et un sel de protamine
WO2006058923A1 (fr) 2004-12-03 2006-06-08 Novo Nordisk A/S Composés hétéroaromatiques activants de glucokinase
WO2006072881A1 (fr) 2005-01-10 2006-07-13 Cortendo Invest Ab Procedes et compositions pour le traitement du diabete, du syndrome metabolique et d'autres conditions
EP2292653A1 (fr) 2005-02-02 2011-03-09 Novo Nordisk A/S Nouveaux dérivés d'insuline
WO2006082204A1 (fr) 2005-02-02 2006-08-10 Novo Nordisk A/S Derives d'insuline
EP2256130A1 (fr) 2005-02-02 2010-12-01 Novo Nordisk A/S Nouveaux dérivés d'insuline
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007003581A1 (fr) 2005-06-30 2007-01-11 Novo Nordisk A/S Acides phénoxyacétiques en tant qu'activateurs de rapp-delta
EP2298742A1 (fr) 2005-06-30 2011-03-23 High Point Pharmaceuticals, LLC Acides phénoxyacétiques en tant qu'activateurs PPAR delta
EP2386554A1 (fr) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Composés actives sur le recepteur histamine H3
EP2233470A1 (fr) 2005-07-04 2010-09-29 High Point Pharmaceuticals, LLC Antagonists du receptor histamine H3
EP2377856A1 (fr) 2005-07-14 2011-10-19 Novo Nordisk A/S Activateurs de la glucokinase d'urée
WO2007006814A1 (fr) 2005-07-14 2007-01-18 Novo Nordisk A/S Activateurs de l'uree glucokinase
WO2007015805A1 (fr) 2005-07-20 2007-02-08 Eli Lilly And Company Composés joints en position 1-amino
WO2007033266A2 (fr) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Administration d'inhibiteurs de dipeptidyl peptidase
US7598398B2 (en) 2005-10-13 2009-10-06 Merck & Co., Inc. Acyl indoles, compositions containing such compounds and methods of use
EP1801098A1 (fr) 2005-12-16 2007-06-27 Merck Sante Dérivés de 2-Adamantylurea comme inhibiteurs de 11B-HSD1
EP2386540A1 (fr) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Nouveaux composés, leur utilisation et préparation
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007110364A1 (fr) 2006-03-28 2007-10-04 High Point Pharmaceuticals, Llc Benzothiazoles presentant une activité sur le récepteur h3 de l'histamine
US7935713B2 (en) 2006-05-16 2011-05-03 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007137968A1 (fr) 2006-05-29 2007-12-06 High Point Pharmaceuticals, Llc Benzodioxolylcyclopropylpipérazinylpyridazines
EP2402324A1 (fr) 2006-05-29 2012-01-04 High Point Pharmaceuticals, LLC Benzodioxolylcyclopropylpipérazinylpyridazines
US9198906B2 (en) 2006-10-02 2015-12-01 Cortendo Ab (Publ) Ketoconazole enantiomer in humans
US7968589B2 (en) 2006-10-03 2011-06-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7687534B2 (en) 2006-10-03 2010-03-30 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2008059025A1 (fr) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Nouvelles 2-(2-hydroxyphényl) benzothiadiazines utilisées pour traiter l'obésité et le diabète
US8278327B2 (en) 2006-11-21 2012-10-02 Omeros Corporation PDE10 inhibitors and related compositions and methods
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2008074384A1 (fr) 2006-12-21 2008-06-26 Merck Patent Gmbh Dérivés de 2-adamantyle-butyramide en tant qu'inhibiteurs sélectifs de 11βêta-hsd1
WO2008084044A1 (fr) 2007-01-11 2008-07-17 Novo Nordisk A/S Activateurs de l'urée glucokinase
EP2107908A4 (fr) * 2007-02-02 2011-07-20 Redpoint Bio Corp Utilisation d'un inhibiteur de trpm5 pour réguler une sécrétion d'insuline et de glp-1
US8193168B2 (en) 2007-02-02 2012-06-05 Redpoint Bio Corporation Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release
EP2107908A2 (fr) * 2007-02-02 2009-10-14 Redpoint Bio Corporation Utilisation d'un inhibiteur de trpm5 pour réguler une sécrétion d'insuline et de glp-1
WO2009127321A1 (fr) 2008-04-18 2009-10-22 Merck Patent Gmbh, Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs de fxr
EP2110374A1 (fr) 2008-04-18 2009-10-21 Merck Sante Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR
FR2932481A1 (fr) * 2008-06-13 2009-12-18 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
CN102124001A (zh) * 2008-06-13 2011-07-13 赛诺菲-安万特 2-氧代烷基-1-哌嗪-2-酮衍生物、其制备方法和治疗用途
KR101601999B1 (ko) 2008-06-13 2016-03-17 사노피 2-옥소-알킬-1-피페라진-2-온의 유도체, 그의 제조 방법 및 그의 치료 용도
FR2932482A1 (fr) * 2008-06-13 2009-12-18 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
US8247404B2 (en) 2008-06-13 2012-08-21 Sanofi Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
CN102124001B (zh) * 2008-06-13 2014-01-22 赛诺菲-安万特 2-氧代烷基-1-哌嗪-2-酮衍生物、其制备方法和治疗用途
WO2009150387A1 (fr) * 2008-06-13 2009-12-17 Sanofi-Aventis Derives de 2-oxo-alkyl-1-piperazin-2-one, leur preparation et leur application en therapeutique
EA019924B1 (ru) * 2008-06-13 2014-07-30 Санофи-Авентис Производные 2-оксоалкил-1-пиперазин-2-она, их получение и их применение в терапии
US20100035932A1 (en) * 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
EP2676959A1 (fr) 2008-11-13 2013-12-25 Merck Sharp & Dohme Corporation Combinaison thérapeutique contenant des aminotetrahydropyrannes en tant qu'inhibiteurs de dipeptidyl peptidase-IV pour le traitement ou la prévention des diabètes
EP2676961A1 (fr) 2008-11-13 2013-12-25 Merck Sharp & Dohme Corporation Combinaison thérapeutique contenant des aminotetrahydropyrannes en tant qu'inhibiteurs de dipeptidyl peptidase-IV pour le traitement ou la prévention des diabètes
EP2676960A1 (fr) 2008-11-13 2013-12-25 Merck Sharp & Dohme Corp. Combinaison thérapeutique contenant des aminotetrahydropyrannes en tant qu'inhibiteurs de dipeptidyl peptidase-IV pour le traitement ou la prévention des diabètes
WO2010056717A1 (fr) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Amines bicycliques substituées pour le traitement du diabète
WO2010059618A1 (fr) 2008-11-21 2010-05-27 High Point Pharmaceuticals, Llc Adamantylbenzamides
WO2011011508A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés d’oxazépine benzofusionnés en tant qu’inhibiteurs de la coenzyme-stéaroyle a delta-9 désaturase
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
WO2011019538A1 (fr) 2009-08-13 2011-02-17 Merck Sharp & Dohme Corp. Composés cyclopropyle substitués, compositions contenant de tels composés et procédés de traitement
WO2011028455A1 (fr) 2009-09-02 2011-03-10 Merck Sharp & Dohme Corp. Aminotétrahydropanes utilisés comme inhibiteurs de la dipeptyl peptidase-iv pour traiter ou prévenir le diabète
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
US8765728B2 (en) 2009-11-16 2014-07-01 Mellitech [1,5]-diazocin derivatives
WO2011058193A1 (fr) 2009-11-16 2011-05-19 Mellitech Dérivés de [1,5]-diazocine
US8957211B2 (en) 2009-12-14 2015-02-17 Sanofi (Heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors
US8906924B2 (en) 2009-12-14 2014-12-09 Sanofi (heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors
US8518947B2 (en) 2009-12-14 2013-08-27 Sanofi (Heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors
US8580790B2 (en) 2009-12-14 2013-11-12 Sanofi (Heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors
US9340523B2 (en) 2009-12-30 2016-05-17 Fochon Pharma, Inc. Certain dipeptidyl peptidase inhibitors
US8648073B2 (en) 2009-12-30 2014-02-11 Fochon Pharma, Inc. Certain dipeptidyl peptidase inhibitors
WO2011097079A1 (fr) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase 1 régulant le signal d'apoptose
WO2011103256A1 (fr) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Aminotétrahydrothiopyranes substitués et dérivés de ceux-ci utilisés en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le cadre du traitement du diabète
WO2011104378A1 (fr) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides de traitement de l'obésité
WO2011104379A1 (fr) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides pour le traitement de l'obésité
WO2011117415A1 (fr) 2010-03-26 2011-09-29 Novo Nordisk A/S Nouveaux analogues du glucagon
WO2011117416A1 (fr) 2010-03-26 2011-09-29 Novo Nordisk A/S Nouveaux analogues du glucagon
WO2011146358A1 (fr) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
WO2012024183A1 (fr) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Composés spiroxazolidinone
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US8933104B2 (en) 2010-12-23 2015-01-13 Pfizer Inc. Glucagon receptor modulators
US8809342B2 (en) 2010-12-23 2014-08-19 Pfizer Inc. Glucagon receptor modulators
US9056834B2 (en) 2010-12-23 2015-06-16 Pfizer Inc. Glucagon receptor modulators
US9452999B2 (en) 2011-02-08 2016-09-27 Pfizer Inc. Glucagon receptor modulators
US8507533B2 (en) 2011-02-08 2013-08-13 Pfizer Inc. Glucagon receptor modulators
US9073871B2 (en) 2011-02-08 2015-07-07 Pfizer Inc. Glucagon receptor modulators
US8859591B2 (en) 2011-02-08 2014-10-14 Pfizer Inc. Glucagon receptor modulators
WO2012130866A1 (fr) 2011-03-28 2012-10-04 Novo Nordisk A/S Nouveaux analogues de glucagon
US8957062B2 (en) 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012164071A1 (fr) 2011-06-02 2012-12-06 Intervet International B.V. Dérivés d'imidazole
US9006228B2 (en) 2011-06-16 2015-04-14 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
US9139538B2 (en) 2011-07-22 2015-09-22 Pfizer Inc. Quinolinyl glucagon receptor modulators
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
US9486505B2 (en) 2011-09-23 2016-11-08 Novo Nordisk A/S Glucagon analogues
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
US9422266B2 (en) 2011-09-30 2016-08-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2013048916A1 (fr) 2011-09-30 2013-04-04 Merck Sharp & Dohme Corp. Composés de cyclopropyle substitués, compositions contenant ces composés et méthodes de traitement
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
WO2013068328A1 (fr) 2011-11-07 2013-05-16 Intervet International B.V. Composés d'acide bicyclo[2.2.2]octan-1-ylcarboxylique comme inhibiteurs de la dgat-1
WO2013068439A1 (fr) 2011-11-09 2013-05-16 Intervet International B.V. Composés 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazépine comme inhibiteurs de dgat1
US9029403B2 (en) 2011-11-10 2015-05-12 Memorial Sloan-Kettering Cancer Center Treatment of ovarian cancer with benzylidenebenzohydrazides
US9018224B2 (en) 2011-11-15 2015-04-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
US9763940B2 (en) 2011-12-20 2017-09-19 Sanofi Therapeutic use of P75 receptor antagonists
WO2013122920A1 (fr) 2012-02-17 2013-08-22 Merck Sharp & Dohme Corp. Inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prévention du diabète
WO2013155600A1 (fr) 2012-04-16 2013-10-24 Kaneq Pharma Dérivés de phosphonates aromatiques fusionnés utilisés comme précurseurs d'inhibiteurs de ptp-1b
WO2014018350A1 (fr) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Traitement du diabète par administration d'inhibiteurs de dipeptidyl peptidase-iv
US9867869B2 (en) 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US9751927B2 (en) 2013-04-18 2017-09-05 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2015112465A1 (fr) 2014-01-24 2015-07-30 Merck Sharp & Dohme Corp. Dérivés d'isoquinoline utilisés comme inhibiteurs de mgat2
WO2015160678A1 (fr) 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Complexe de tannate de sitagliptine
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
EP3825324A1 (fr) 2014-10-24 2021-05-26 Merck Sharp & Dohme Corp. Co-agonistes des récepteurs du glucagon et du glp-1
WO2016065090A1 (fr) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonistes des récepteurs du glucagon et du glp-1
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US11498896B2 (en) 2014-12-19 2022-11-15 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2017062334A1 (fr) 2015-10-05 2017-04-13 Merck Sharp & Dohme Corp. Conjugués anticorps-peptides ayant une activité agoniste au niveau des récepteurs au glucagon et au peptide-1 similaire au glucagon
WO2018034917A1 (fr) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Composés utiles pour modifier les taux d'acides biliaires pour le traitement du diabète et de maladies cardiométaboliques.
WO2018034918A1 (fr) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Composés utiles pour modifier les taux d'acides biliaires pour le traitement du diabète et de maladies cardiométaboliques.
WO2018167194A1 (fr) 2017-03-15 2018-09-20 Novo Nordisk A/S Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
WO2019219714A1 (fr) 2018-05-15 2019-11-21 Novo Nordisk A/S Composés capables de se lier au récepteur de la mélanocortine 4
WO2020053414A1 (fr) 2018-09-14 2020-03-19 Novo Nordisk A/S Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4
WO2020074958A1 (fr) 2018-10-12 2020-04-16 Strongbridge Dublin Limited Lévokétoconazole pour le traitement de l'hyperplasie surrénale congénitale et de l'aldostéronisme primaire
WO2020205688A1 (fr) 2019-04-04 2020-10-08 Merck Sharp & Dohme Corp. Inhibiteurs d'histone désacétylase -3 utiles pour le traitement du cancer, de l'inflammation, de maladies neurodégénératives et du diabète
EP3842449A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes d'oléfine agrafés du glucagon et récepteurs glp-1
EP3842061A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes triazoles agrafés des récepteurs du glucagon et du glp-1
EP3842060A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes lactames agrafés des récepteurs du glucagon et du glp-1

Also Published As

Publication number Publication date
HUP0002373A3 (en) 2000-11-28
AU749271B2 (en) 2002-06-20
NO996550D0 (no) 1999-12-29
CN1267281A (zh) 2000-09-20
AU7908398A (en) 1999-01-25
NO996550L (no) 2000-02-29
KR20010020590A (ko) 2001-03-15
WO1999001423A8 (fr) 1999-05-14
EP0994848A1 (fr) 2000-04-26
PL337781A1 (en) 2000-09-11
JP2003514508A (ja) 2003-04-15
BR9810378A (pt) 2000-08-29
HUP0002373A2 (hu) 2000-10-28
IL133377A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
EP0994848A1 (fr) Antagonistes/agonistes inverses du glucagon
US6613942B1 (en) Glucagon antagonists/inverse agonists
RU2280025C2 (ru) Новые производные аминодикарбоновых кислот, обладающие фармацевтическими свойствами
EP1663979B1 (fr) Composes de phenyle ou de pyridyle amide utiles comme antagonistes de la prostaglandine e2
JP2005505618A (ja) ｐ３８キナーゼ阻害剤としてのビフェニル誘導体
US20040082798A1 (en) Novel amino dicarboxylic acid derivatives with pharmaceutical properties
MXPA05006701A (es) Moduladores de asma y de inflacion alergica.
AU2002253010A1 (en) Acylated indanyl amines and their use as pharmaceuticals
JPH09511529A (ja) 芳香族化合物
EP1373191A1 (fr) Amines indanyle acyles et leurs utilisation comme agents pharmaceutiques
WO2003004458A1 (fr) Composes nouveaux
ZA200201138B (en) Novel dicarboxylic acid derivatives with pharmaceutical properties.
KR20040082425A (ko) Ｐ38 억제제로 유용한 니코틴아미드 유도체
ZA200600819B (en) Cycloalkylidene compounds as modulators of estrogen receptor
SK12892001A3 (sk) Zlúčeniny a prostriedky ako inhibítory proteázy
EP1951216A2 (fr) Composes chimiques
JP2006504767A (ja) フェニル化合物
JP2008503588A (ja) 化学化合物
EP1113000A1 (fr) Derives de benzene et leur utilisation medicale
US7345075B2 (en) 1,2 diarylbenzimidazoles and their pharmaceutical use
KR102132744B1 (ko) 당뇨병 치료에 유용한 이미다조피리딘 유도체들
JP2000001431A (ja) 尿酸排泄剤
JP2001139575A (ja) 新規ピラゾロピリジン誘導体
JPH033658B2 (fr)
WO1998057935A1 (fr) Derives d'acide 2-sulfamoylbenzoique

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 133377

Country of ref document: IL

Ref document number: 98808125.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWE Wipo information: entry into national phase

Ref document number: PV1999-4467

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/A/1999/011896

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2294046

Country of ref document: CA

Ref document number: 2294046

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998929244

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 79083/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1019997012562

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1998929244

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1999-4467

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997012562

Country of ref document: KR

AK Designated states

Kind code of ref document: B8

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: B8

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 02/99 UNDER (22) REPLACE THE EXISTING DATE BY "30.06.98"

WWG Wipo information: grant in national office

Ref document number: 79083/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1019997012562

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998929244

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: PV1999-4467

Country of ref document: CZ